Trial reportScientific reports2025
New design peripheral defocus spectacle lens vs. single-vision for slowing myopia progression in children: randomized controlled trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports the 1-year results of a 2-year multicenter prospective randomized, controlled, double-masked trial aimed to determine whether Myoslow lenses (Crystal Optic Industries Ltd., Acre, Israel) based on the peripheral defocus mechanism of action can slow myopia progression. Children aged 6-12 years with myopia between - 1.00 D and - 5.00 D and astigmatism ≤ 1.50 D (N = 121) received either Myoslow (treatment) or single vision (control) spectacle lenses. The mean change in spherical equivalent refractive error from baseline was - 0.46 D in the treatment group and - 0.65 D in the control group (p = 0.015), with myopia progression slowed by 0.19 D (29.5%). The mean change in axial length was 0.27 mm in the treatment group and 0.36 mm in the control group (p = 0.002), with myopia progression slowed by 0.09 mm (23.6%). Younger age was the only covariate significantly associated with the treatment effect across both outcome measures, with a significant correlation between the treatment effects in the two measures (R = - 0.71, p < 0.001). Treatment was well tolerated, with only one ocular complication: myopia progression (0.08%). Myoslow lenses effectively and safely slow myopia progression in children, with greater benefit in younger ages compared to single vision lenses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.